« Back
Home /
CDK9-IN-2

CDK9-IN-2

Manufacturer	MedChem Express
Category	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Heart & Blood Cancer Lymphatic System Cancer
Type	Inhibitors
Specific against	other
Clone	N/A
Amount	10mM/1mL
Item no.	HY-16462-10mM
Targets	CDK
CASRN	1263369-28-3
eClass 6.1	30220300
eClass 9.0	32160605
Available
Product Description	CDK9-IN-2 is a special cyclin-dependent kinase 9 (CDK9) inhibitor, extracted from patent WO/2012131594A1, compound CDKI(8), has an IC50 of 5 nM and 7 nM in H929 multiple myeloma(MM) cell line (72 hours) and A2058 skin cell line (72 hours), respectively.
StorageTemperature	-20°C, 3 years; 4°C, 2 years (Powder)
Shipping	Room Temperature
Manufacturers Applications	COVID-19-anti-virus
MolecularWeight	425.93
Clinical_Information	No Development Reported
Manufacturers Research_Area	Cancer
Solubility	DMSO : 50 mg/mL (ultrasonic)
Manufacturers Target	CDK
Isoform	CDK9
Pathway	Cell Cycle/DNA Damage
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-16462-10mM-safety-datasheet.pdf